TAU professor Judith Berman named as new member of EMBO

Berman is an expert on Candida albicans, a pathogenic yeast used to study how can a genome change in response to stress.

June 29, 2019 02:12
1 minute read.



Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Tel Aviv University Professor Judith Berman was named one of 56 new members of the European Molecular Biology Organization (EMBO), which is one of the most respected research group in the world, a press release by American Friends of Tel Aviv University reported on Friday. 
Having started her scientific career at the University of Minnesota, Berman had focused for nearly 20 years on the study of drug resistance and tolerance in a type of yeast called Candida albicans. 
During a May interview with the podcast ‘We Talk Science’ she explained that these types of yeast “are a lot like us,” meaning humans.

However, as they evolve much more rapidly than humans it is possible to see how they adapt to drugs in the lab before your eyes, she explained. 
"We investigate the interplay between chromosome instability, membrane and cell wall dynamics," she wrote for the EMBO site. 


While there are six classes of drugs that can be used to treat bacteria there are only three classes of drugs that can treat Candida albicans.

As this type of yeast can seriously endanger the lives of humans who have a weak immune system, it kills hundreds of thousands of people annually around the world, it’s important to understand how it is genetically able to acquire resistance to the treatments we currently have. 
“While antibiotics can treat bacteria, the cell of the yeast is a lot like a human cell, and so it is much harder to find drugs that will only target the yeast and not healthy human tissues,” she explained in an interview to the science site Hayadan. 
"Prof. Berman's election to EMBO is a strong recognition of her research, which is at the forefront of molecular biology of pathogenic yeasts," said Prof. Abdussalam Azem, dean of the Wise Faculty.
EMBO will formally welcome its new members and associate members October 29-31 at the Annual Members' Meeting in Heidelberg.          

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

COW’S MILK can be replaced with almond or coconut milk
July 13, 2019
Alternatively Speaking: Head, shoulders, knees and toes


Cookie Settings